Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22719416 | 0.88 | MRGPRX4 (0.47) | MRGPRX4CFTRCA12CA1CA2 | |
| SCHEMBL19879280 | 0.86 | MAPT (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4691963 | 0.86 | CA12 (0.50) | MRGPRX4CFTRCA12CA1CA2 | |
| SCHEMBL5943406 | 0.83 | CA12 (0.64) | MRGPRX4CFTRCA12CA1CA2 | |
| SCHEMBL28195998 | 0.83 | MRGPRX4 (0.48) | MRGPRX4CFTRCA12CA1CA2 | |
| SCHEMBL16647662 | 0.83 | MRGPRX4 (0.51) | MRGPRX4CFTRCA12CA1CA2 | |
| SCHEMBL1998616 | 0.83 | CES2 (0.60) | MRGPRX4CFTRCA12CA1CA2 | |
| SCHEMBL421443 | 0.83 | CFTR (0.67) | MRGPRX4CFTRCA12CA1CA2 | |
| SCHEMBL5405115 | 0.82 | MRGPRX4 (0.48) | MRGPRX4CFTRCA12CA1CA2 | |
| SCHEMBL11336074 | 0.82 | CFTR (0.70) | MRGPRX4CFTRCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| EP-4536660-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2025-04-16 | — | — | EP | disclosed |
| CN-114040911-B | As NAV1.8 2, 3-Dihydro-quinazoline Compounds as inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-10-22 | — | — | CN | disclosed |
| WO-2023238065-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-12-14 | — | — | WO | disclosed |
| EP-4262978-A1 | CHEMICAL COMPOUNDS USEFUL FOR INHIBITING NAV1.8 VOLTAGE-GATED SODIUM CHANNELS AND TREATING NAV1.8 MEDIATED DISEASES | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-10-25 | — | — | EP | disclosed |
| CN-116710463-A | Chemical compounds for inhibiting NAV1.8 voltage-gated sodium channels and for treating NAV1.8 mediated diseases | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-06 | — | — | US | disclosed |
| WO-2022129283-A1 | CHEMICAL COMPOUNDS USEFUL FOR INHIBITING NAV1.8 VOLTAGE-GATED SODIUM CHANNELS AND TREATING NAV1.8 MEDIATED DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129283-A1 | CHEMICAL COMPOUNDS USEFUL FOR INHIBITING NAV1.8 VOLTAGE-GATED SODIUM CHANNELS AND TREATING NAV1.8 MEDIATED DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| EP-3990436-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2022-05-04 | — | — | EP | disclosed |
| CN-114040911-A | As NAV1.8 inhibitors of 2, 3-dihydroquinazoline compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-02-11 | — | — | CN | disclosed |
| WO-2020261114-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020261114-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-30 | — | — | WO | disclosed |
| US-5514719-A | Fungicidal phenylbenzamides | RHONE-POULENC AGROCHIMIE (FR) | 1996-05-07 | — | — | US | disclosed |
| CN-1081179-A | Fungicidal agents phenylbenzamaide and preparation method thereof | RHONE POULENC AGROCHIMIE (FR) | 1994-01-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN5A | MRGPRX4 3007/4885CFTR 1390/4885CA12 3463/4885 |
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN1A, SCN1B | MRGPRX4 510/4885CFTR 402/4885CA12 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.